Activating Fc gamma receptors (FccRs) in hematopoietic cells serve to remove antibody-opsonized antigens, including dengue virus (DENV), from systemic circulation. While neutralizing antibody concentrations provide humoral immunity, cross-reactive or sub-neutralizing levels of antibody can result in antibody-dependent enhancement of DENV infection that increases overall viral burden. Recently, it has been suggested that the antibody levels needed for DENV neutralization differs when different FccR is engaged. If this is true, the threshold titer used to infer immunity should be influenced by FccR usage. Here, using cells that express both activating and inhibitory FccRs, we show that the type of FccR engaged during phagocytosis can influenc...
<div><p>Antibody dependent enhancement (ADE) has most often been associated with dengue virus (DENV)...
SummaryAntibodies protect against homologous Dengue virus (DENV) infection but can precipitate sever...
Background. Recent trials of recombinant, live-attenuated chimeric yellow fever-dengue tetravalent d...
Activating Fc gamma receptors (FcγRs) in hematopoietic cells serve to remove antibody-opsonized anti...
AbstractSevere dengue virus (DENV) infection is epidemiologically linked to pre-existing anti-DENV a...
AbstractAlthough several vaccine candidates are presently in various phases of clinical trials, the ...
Viruses must evade the host innate defenses for replication and dengue is no exception. During secon...
<div><h3>Background</h3><p>Progress in dengue vaccine development has been hampered by limited under...
ABSTRACT Dengue is caused by infection with any one of four dengue viruses (DENV); the risk of sever...
Antibody-dependent enhancement (ADE) of dengue virus infection occurs when neutralizing antibodies a...
AbstractWe examined dengue virus immune complex–phagocyte interaction with respect to a single Fc re...
Background: Antibodies are critical responses to protect the host from dengue virus(DENV) infection....
AbstractHuman monocytes are susceptible to dengue virus (DV) infection through an FcR-dependent path...
Antibodies protect against homologous Dengue virus (DENV) infection but can precipitate severe dengu...
Antibody-dependent enhancement (ADE) of dengue virus infection occurs when eutralizing antibodies at...
<div><p>Antibody dependent enhancement (ADE) has most often been associated with dengue virus (DENV)...
SummaryAntibodies protect against homologous Dengue virus (DENV) infection but can precipitate sever...
Background. Recent trials of recombinant, live-attenuated chimeric yellow fever-dengue tetravalent d...
Activating Fc gamma receptors (FcγRs) in hematopoietic cells serve to remove antibody-opsonized anti...
AbstractSevere dengue virus (DENV) infection is epidemiologically linked to pre-existing anti-DENV a...
AbstractAlthough several vaccine candidates are presently in various phases of clinical trials, the ...
Viruses must evade the host innate defenses for replication and dengue is no exception. During secon...
<div><h3>Background</h3><p>Progress in dengue vaccine development has been hampered by limited under...
ABSTRACT Dengue is caused by infection with any one of four dengue viruses (DENV); the risk of sever...
Antibody-dependent enhancement (ADE) of dengue virus infection occurs when neutralizing antibodies a...
AbstractWe examined dengue virus immune complex–phagocyte interaction with respect to a single Fc re...
Background: Antibodies are critical responses to protect the host from dengue virus(DENV) infection....
AbstractHuman monocytes are susceptible to dengue virus (DV) infection through an FcR-dependent path...
Antibodies protect against homologous Dengue virus (DENV) infection but can precipitate severe dengu...
Antibody-dependent enhancement (ADE) of dengue virus infection occurs when eutralizing antibodies at...
<div><p>Antibody dependent enhancement (ADE) has most often been associated with dengue virus (DENV)...
SummaryAntibodies protect against homologous Dengue virus (DENV) infection but can precipitate sever...
Background. Recent trials of recombinant, live-attenuated chimeric yellow fever-dengue tetravalent d...